• 13 Nov 19

Mereo BioPharma CEO confident as it moves forward with pivotal Setrusumab study

Mereo BioPharma CEO confident as it moves forward with pivotal Setrusumab study

    • 142 views

 

Mereo BioPharma's (LON:MPH) Denise Scots-Knight explains why she's confident in the potential of their lead drug setrusumab despite it not meeting its primary endpoint in a recent Phase 2b study.

The drug's being developed as a treatment for osteogenesis imperfecta which is also known as brittle bone disease.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Genflow CEO on manufacturing deal, IP wins & dog study update

Companies: Genflow Biosciences Plc

Scancell fast-tracks melanoma study with NHS

Companies: Scancell Holdings Plc

Genflow CEO on manufacturing deal, IP wins & dog study update

Companies: Genflow Biosciences Plc

Genflow Bioscinces eyes glaucoma Cure with SIRT6 breakthrough

Companies: Genflow Biosciences Plc

Genflow's dog gene trial: £500K raised for SIRT6 therapy

Companies: Genflow Biosciences Plc

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Companies: Genflow Biosciences Plc

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top